Efficacy of Frontalis Muscle Flap Suspension in Treating Moderate to Severe Blepharoptosis

Abstract

Purpose: This study aims to evaluate the efficacy of frontalis muscle flap suspension in treating moderate to severe blepharoptosis. Study subjects: 54 eyes of 47 moderate to severe blepharoptosis patients (aged 17.34 ± 9.17 years, 18 males, 29 females). Study design: Prospective uncontrolled clinical trial. Results: Following frontalis muscle flap suspension surgery, there was a statistically significant improvement (p<0.001) in margin reflex distance 1 (MRD1) and palpebral fissure height (PFH), from 0.009 ± 0.60 mm and 5.59 ± 0.68 mm (pre-operation) to 2.68 ± 1.10 mm and 8.26 ± 1.14 mm (1 week after operation), 3.63 ± 0.77 mm and 9.24 ± 0.85 mm (6 months after operation), 3.45 ± 0.80 mm and 9.02 ± 0.89 mm (12 months after operation). At the 12th month after operation, it was found that severe lagophthalmos, lid lag on down-gaze and forehead hypoesthesia were present in 7.4%, 9.3% and 14.0% of all treated eyes, respectively. Excellent functional results were determined in 66,0% of procedures postoperatively, with 31,9% and 2,1% rated as good and unsatisfactory. In terms of cosmetic results, 78,7%, 19,1% and 2,1% of cases were rated as excellent, good and unsatisfactory, respectively. Conclusion: Majority of case results were excellent (78,7%) and good (19,1%), unsatisfactory cases 2,1%.